Analytical Data
-
Gene name
Cyp3a25
- Application
-
Alternative Names
(CYPIIIA25)
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O09158
-
Expression Region
1-503aa
-
Molecular Weight
65.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP3A25 is a member of the cytochrome P450 (CYP) family, which plays a crucial role in the metabolism of various endogenous and exogenous compounds, including drugs, hormones, and toxins. This enzyme is primarily expressed in the liver and intestines, contributing significantly to the pharmacokinetics of many therapeutic agents. The study of CYP3A25 is particularly important due to its potential implications in drug metabolism variability among individuals, which can influence efficacy and toxicity. Genetic polymorphisms in the CYP3A gene family have been associated with altered enzyme activity, leading to differences in drug response and side effects. Understanding the structure and function of CYP3A25, along with its substrate specificity and interactions with various drugs, can provide insights into personalized medicine approaches. Researchers have focused on recombinant protein expression of CYP3A25 to investigate its biochemical properties, substrate affinity, and role in drug metabolism. This knowledge is essential for optimizing drug dosing regimens and minimizing adverse drug reactions, especially in populations with high prevalence of genetic variants. Therefore, ongoing studies into CYP3A25 recombinant proteins are pivotal for advancing pharmacogenomics and enhancing therapeutic outcomes in clinical practice.
